[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614759":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":58,"collaborators":34,"id":60,"slug":34,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":34,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":34,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":34,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: Single Ascending Dose","EXPERIMENTAL","Participants will be randomized to receive a single dose of VX-581.",[13],"Drug: VX-581",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo: Part A","PLACEBO_COMPARATOR","Participants will be randomized to receive a single dose of placebo matched to VX-581.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B: Multiple Ascending Dose","Participants will be randomized to receive multiple doses of VX-581.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Placebo: Part B","Participants will be randomized to receive multiple doses of placebo matched to VX-581.",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","VX-581","Suspension for Oral Administration.",[9,21],null,{"type":30,"name":36,"description":32,"armGroupLabels":37,"otherNames":34},"Placebo",[15,25],[39],{"name":40,"role":41,"phone":42,"phoneExt":34,"email":43},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":34},"Altasciences - Kansas City","RECRUITING","Overland Park","Kansas","66212","United States",{"type":53,"coordinates":54},"Point",[55,56],-94.67079,38.98223,{"lat":56,"lon":55},{"type":59,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100614759",false,"NCT07283770","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg\u002Fm\\^2)\n* A total body weight of more than (\\>) 50 kg\n* Male and Female participants of non-childbearing potential\n\nKey Exclusion Criteria:\n\n* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":71,"type":72},128,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.",[78],"Cystic Fibrosis","2026-05-13",{"date":81,"type":82},"2026-05-18","ACTUAL",{"date":84,"type":82},"2025-12-09",{"date":86,"type":72},"2026-11-19",{"name":5,"class":6},1]